The three indexes were down in early trading, and the index of the 50 index of the science and technology innovation fell nearly 3%. The stock market showed a general fall pattern, and the medical beauty, CRO, Baijiu and other plates were all down. Yesterday, the strong lithium battery plate rose and fell. Short term mood is ebb. On the plate, Hong Meng, fluorine chemical industry, agriculture, real estate and other sectors are among the top gainers, and the medical beauty, CRO, Baijiu, food and beverage sectors are among the top. A shares continued to decline in the afternoon, with the gem index falling more than 3 per cent, Shenzhen composite index down nearly 1.3 per cent and Shanghai index down 0.8 per cent. The traditional Chinese medicine and the third generation semiconductor plate were weak, and the pharmaceutical and medical sector led the decline.
For pharmaceutical stocks, especially cro concept stocks, the collective decline, some market views suggest that it may be related to the excessive increase of the previous sector, and is currently normal technical adjustment, and some market views suggest that it may have a certain relationship with the recent policy trends of the industry. For example, on July 2, the drug review center of the State Drug Administration issued a notice of public solicitation of the opinions of the guiding principles for clinical research and development of anti-tumor drugs guided by clinical value. The notice noted that the fundamental purpose of the drug listing was to address the needs of patients. It has become a general consensus that drug research and development should focus on the needs of patients and be guided by clinical value. At present, the research and development of anti-tumor drugs in China is in the stage of rapid development; Cancer patients have higher expectations for drug safety, treatment experience and quality of life. The research and development of anti-tumor drugs, from determining the direction of research and development to carrying out clinical trials, should implement the concept of taking clinical needs as the core, and carry out the research and development of anti-tumor drugs guided by clinical value.
1. The Hong Kong Stock Exchange will adopt the t+2 IPO settlement cycle
Hong Kong exchange and Clearing House Limited today announced that it will implement the launch of a new platform fini to comprehensively simplify and digitize the Hong Kong IPO process. The current t+5 settlement period for Hong Kong listed new shares is recommended in the fini framework consultation document to shorten the relevant period to t+1. After consulting the market and considering the market opinions and operational needs, the Hong Kong Stock Exchange will implement the promotion of fini as a unified platform for all new shares in the future, but the t+2 settlement cycle will be adopted first, which shall be implemented as early as the fourth quarter of 2022.
2. Blue light development: the news report of China bank trust and Vanke to be invested is not true
Blue light development issued a Clarification Announcement. Some media reports mentioned that the trust board of Bank of China and Vanke would take part in blue light development. After verification, the above-mentioned news report is not true.
3. Huaxia happiness people familiar with the situation: debt resolution plan is expected to be released this month
According to the people familiar with Huaxia happiness, the plan for China happiness debt resolution is expected to be released this month.
4. The Fed kept the benchmark interest rate unchanged at 0.1 percent, consistent with expectations
The RBA kept the benchmark interest rate and three-year bond yield target unchanged at 0.1%, which was in line with market expectations. The RBA announced plans for a third round of QE. The Australian Federal Reserve said it continued to use the april2024 bond as the target bond for the yield of the three-year treasury bonds; It is planned to buy $4billion a week until mid November.
Haitong Securities said that we judge that the short-term and fast upward period of A-share market has passed, and the later A-share market is probably a structural market with a fluctuating upward trend, showing a slow overall pattern, and the market does not lack investment opportunities. It is suggested to focus on the high growth or higher than expected sectors of the performance of the report, and fully consider the industry logic, industry prosperity, and the company’s quality and valuation. We will continue to focus on the main line of high prosperity, and focus on the four main lines of new energy, independent and controllable science and technology, national defense and security, and intelligent manufacturing, so as to seize the new entry opportunity brought about by the structural fluctuation of the market.
Galaxy Securities said that A-share market is still in the volatile rising market, in the context of the lack of continuity of the theme, the importance of rhythm grasp is more prominent, looking for certainty. The core driving force of A-share is still the evolution of domestic economy. In July, it entered the intensive period of performance disclosure, and the focus is still performance + interim report. Anchor the long-term investment opportunities of core assets, and focus on the high-quality “core assets” with high forecast flexibility and strong profitability. It is suggested to pay attention to: 1) growth companies with high flexibility in the Chinese newspaper; 2) We are optimistic about coal, oil and other resource industries with upward momentum, improved resource supply and demand, and partial consumption attributes; 3) Continue to be optimistic about the long-term investment value of the pharmaceutical sector; 4) Focus on new energy vehicle, semiconductor, photovoltaic and other industries with high growth performance expectations.